Familial Adenomatous Polyposis – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Familial Adenomatous Polyposis – Pipeline Review, H2 2018’, provides an overview of the Familial Adenomatous Polyposis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis

– The report reviews pipeline therapeutics for Familial Adenomatous Polyposis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Familial Adenomatous Polyposis therapeutics and enlists all their major and minor projects

– The report assesses Familial Adenomatous Polyposis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Familial Adenomatous Polyposis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Familial Adenomatous Polyposis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Cancer Prevention Pharmaceuticals Inc

Cellix Bio Pvt Ltd

Marina Biotech Inc

Thetis Pharmaceuticals LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Familial Adenomatous Polyposis Overview

Familial Adenomatous Polyposis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Familial Adenomatous Polyposis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Familial Adenomatous Polyposis Companies Involved in Therapeutics Development

Cancer Prevention Pharmaceuticals Inc

Cellix Bio Pvt Ltd

Marina Biotech Inc

Thetis Pharmaceuticals LLC

Familial Adenomatous Polyposis Drug Profiles

(celecoxib + lisinopril) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(eflornithine hydrochloride + sulindac) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLX-157 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FAPXIL Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Familial Adenomatous Polyposis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

icosapent ethyl Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pyrvinium pamoate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RMX-1002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-252 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Familial Adenomatous Polyposis Dormant Projects

Familial Adenomatous Polyposis Discontinued Products

Familial Adenomatous Polyposis Product Development Milestones

Featured News & Press Releases

Feb 22, 2018: Cancer Prevention Pharmaceuticals Appoints Willene Brondum Associate Vice President of Regulatory Affairs and Quality Assurance

Nov 21, 2017: Cancer Prevention Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

Sep 18, 2017: FDA Grants “Fast Track” Status to Cancer Prevention Pharmaceuticals’ Lead Drug CPP-1X/sul for Treatment of Familial Adenomatous Polyposis

Jun 12, 2017: Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients

Mar 29, 2017: Marina Biotech to Present Data on IT-102 at 2017 American Association for Cancer Research Annual Meeting

Apr 14, 2016: Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis

Apr 04, 2016: Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis

Jan 27, 2016: Thetis Pharmaceuticals Awarded Key Patent for TP-252

Jan 19, 2016: Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis

Oct 15, 2015: Thetis Pharmaceuticals Presents at BIO Investor Forum in San Francisco

Aug 04, 2015: Thetis Receives Notice of Allowance for Patent Covering Pharmaceutical Composition of Novel Mineral Amino Acid Derivative TP-252

Dec 05, 2013: Phase III Familial Adenomatous Polyposis Trial Now Open for Enrollment

Dec 08, 2011: S.L.A. Pharma Announces Plans For Alfa Phase III Orphan Drug Program For Familial Adenomatous Polyposis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Familial Adenomatous Polyposis, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Familial Adenomatous Polyposis Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2018

Familial Adenomatous Polyposis Pipeline by Cellix Bio Pvt Ltd, H2 2018

Familial Adenomatous Polyposis Pipeline by Marina Biotech Inc, H2 2018

Familial Adenomatous Polyposis Pipeline by Thetis Pharmaceuticals LLC, H2 2018

Familial Adenomatous Polyposis Dormant Projects, H2 2018

Familial Adenomatous Polyposis Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Familial Adenomatous Polyposis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports